Verastem to Present at Upcoming Scientific and Investor Conferences Business Wire CAMBRIDGE, Mass. -- September 18, 2013 Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the Company will present at multiple upcoming scientific and investor conferences. The Verastem presentation information is as follows: Advances in Ovarian Cancer Research: From Concept to Clinic Conference Date: September 18-21, 2013 at the J.W. Marriott Marquis in Miami, FL Presentation 1: Title: FAK inhibitors VS-6063 and VS-4718 preferentially target ovarian cancer stem cells Session: Poster Session A, Thursday, September 19, 4:30 p.m. – 6:30 p.m. Location: Met Ballroom 2-4, Met Ballroom 5-7 Abstract: A39 Presentation 2: Title: Predictive biomarkers for FAK inhibitor sensitivity in ovarian cancer Session: Poster Session B, Friday, September 20, 12:30 p.m. – 2:30 p.m. Location: Met Ballroom 2-4, Met Ballroom 5-7 Abstract: B13 Cancer Advance at Harvard Medical Date: September 19, 2013 at Harvard Medical School in Boston, MA Summary: Verastem executives will join panel discussions throughout the day, addressing industry leaders from Eli Lilly, Harvard University, Johnson & Johnson, Mass General Hospital, and Pfizer among others. President and CEO Robert Forrester will moderate the investor-focused panel “Betting on Oncology: Investor Perspectives” and Chief Business Officer Dan Paterson will join colleagues to discuss efficacy and pricing issues on the “Regulatory and Reimbursement Pressures for Cancer Drugs” panel. Chief Medical Officer Joanna Horobin and Head of Research Jonathan Pachter will also address the audience in two Q&A discussions that will focus on clinical trials in oncology. In addition, Verastem will also be presenting two trials in progress posters describing the registration-directed COMMAND study in mesothelioma and the ongoing combination study of paclitaxel and defactinib in patients with ovarian cancer. Joint MipTec / BioValley Keynote Address Date: September 24, 2013 at 1:40 p.m. CET at the Congress Center Basel, in Basel, Switzerland Presenter: Christoph Westphal, M.D., Ph.D., Verastem Executive Chairman Title: “Drug Innovation in Biotech: Alnylam, Momenta, Sirtris, Verastem” Summary: Dr. Christoph Westphal is delivering the keynote address to the MipTec conference in Basel. In 2012 the keynote was presented by the Head of Research and Development at Regeneron, Dr. George Yancopoulos. This year’s keynote by Dr. Westphal will describe how over the last 13 years, discoveries at MIT and Harvard have been turned into several public biotechnology companies, valued at several hundred million, to several billion in market capitalization. In each case, the team has been motivated by a desire to develop important new medicines for patients with serious illnesses. Working with great people, on fundamentally important novel science, with the chance to make transformative medicines can, if you are lucky, also create value for shareholders. Some of these unifying themes and learnings are captured in briefly describing the similar, and divergent, paths of four companies Dr. Westphal has founded as CEO: Alnylam, Momenta, Sirtris, and Verastem. BioCentury’s 2013 Newsmakers in the Biotech Industry Conference Date: September 27, 2013 at 9:30 a.m. ET at the Millennium Broadway Hotel in New York, NY Webcast: A webcast of the Newsmakers presentation can be accessed by visiting the investors section of the Company’s website at www.verastem.com. A replay of the webcast will be archived on the Verastem website for 30 days following the presentation date. About Verastem, Inc. Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com. Forward-looking statements: Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. Contact: Verastem, Inc. Brian Sullivan, 617-252-9314 email@example.com
American Apparel Got Indication of Interest for $1.30-$1.40 per Share
Verastem to Present at Upcoming Scientific and Investor Conferences
Press spacebar to pause and continue. Press esc to stop.